This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
Two studies within the Liverpool diabetic eye study (reported in three papers) plus one single study outside the Liverpool diabetic eye study were included in the study.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The results of the review were as follows:
Baseline prevalence of sight threatening eye disease was 14.1%.
Sensitivity of the systematic programme was 89% (95% CI: 80% -98%), specificity of the systematic programme was 86% (95% CI: 82% -90%), and compliance rates of the systematic programme, 80%.
Compliance for the opportunistic screening was 78%.
The combined sensitivity of the opportunistic programme was 63%.
The specificity of general practitioners in the opportunistic screening programme was 89%, diabetologists 96%, and optometrists 94%.
The combined specificity for the opportunistic screening programme was 92%.
Measure of benefits used in the economic analysis
The benefit measure was the number of true cases detected.
Direct costs
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A discount rate was used to estimate the annual capital costs. Quantities were reported separately from the costs. Cost items were reported separately. Cost analysis for the intervention covered the direct costs of photographic screening (capital charges and depreciation, etc.), grading (overheads, stationary, etc.), assessment clinic (overheads, stationary, etc.), and external quality control. The cost analysis for the comparator consisted of the cost of screening (staff time, etc.) and cost of follow-up. A health service perspective was adopted in the cost analysis. The cost analysis was based on the ingredient approach rather than costing based on recording individual patient resource use, since it was deemed that the costs in screening programmes are largely fixed or semi-fixed. The costs of systematic screening were calculated on actual resource use with a call-recall system. The average estimates of time spent on direct ophthalmoscopy by six practitioners who regularly carried out screening were used to calculate the general practitioner and diabetologist components. General practitioner costs per minute including overheads were taken from a study published in 1996. The price year was 1996-97.
Indirect Costs
Not considered.
Currency
UK pounds sterling ().
Sensitivity analysis
A series of one-way and two-way sensitivity analyses was used on key variables (apparently not costs) to determine the effect on cost-effectiveness of alternative strategies. 95% confidence intervals were used in the sensitivity analyses performed on sensitivity and specificity of the tests. Threshold values were also calculated.
Estimated benefits used in the economic analysis
The number of true cases detected was 346 in the opportunistic programme and 502 in the systematic screening programme, resulting in an incremental value of 156.
Cost results
The discount rate used to calculate the annual capital costs was 6%. The total cost of screening tests extrapolated for an opportunistic screening programme for a target population of 5,000 (with compliance rate of 78%) was 99,981 versus 104,996 for a systematic screening programme for a target population of 5,000 (with compliance rate of 80%), resulting in an incremental value of 5,015.
Synthesis of costs and benefits
An average cost-effectiveness ratio (as the total cost divided by the number of cases detected) and an incremental costeffectiveness ratio (as the extra cost needed to generate each additional true positive result) were calculated, after replacing opportunistic with systematic screening. The value of the average cost-effectiveness ratio was 289 for the opportunistic screening programme versus 209 for the systematic screening programme. The incremental costeffectiveness ratio for replacing opportunistic by systematic screening was 32. Systematic screening remained more cost effective than opportunistic screening for all values of disease prevalence.
